BDBM250617 US10167273, Example 98::US10544126, Example 96::US11512066, Example 98::US9475795, 96::US9475795, 97::US9475795, 98

SMILES COC(C1CCN(CC1)S(=O)(=O)c1c(C)n[nH]c1C)c1ccc(Cl)cc1

InChI Key InChIKey=OSRKPRHWTFIMHG-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 250617   

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 80nMAssay Description:Prokineticin receptor 1 (PKR1) antagonists may be functionally assessed by measurement of change in intracellular calcium levels induced by Gq mediat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
US Patent

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 80nMAssay Description:Prokineticin receptor 1 (PKR1) antagonists may be functionally assessed by measurement of change in intracellular calcium levels induced by Gq mediat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 80nMAssay Description:The ability of a compound to block the intracellular release of calcium mediated by PK1 in RBL2H3 cells expressing human PKR1 receptors is determined...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2023
Entry Details
US Patent

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 80nMpH: 7.4 T: 2°CAssay Description:Prokineticin receptor 1 (PKR1) antagonists may be functionally assessed by measurement of change in intracellular calcium levels induced by Gq mediat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2017
Entry Details
US Patent

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 160nMAssay Description:Prokineticin receptor 1 (PKR1) antagonists may be functionally assessed by measurement of change in intracellular calcium levels induced by Gq mediat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 160nMAssay Description:The ability of a compound to block the intracellular release of calcium mediated by PK1 in RBL2H3 cells expressing human PKR1 receptors is determined...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2023
Entry Details
US Patent

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 160nMpH: 7.4 T: 2°CAssay Description:Prokineticin receptor 1 (PKR1) antagonists may be functionally assessed by measurement of change in intracellular calcium levels induced by Gq mediat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2017
Entry Details
US Patent

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 160nMAssay Description:Prokineticin receptor 1 (PKR1) antagonists may be functionally assessed by measurement of change in intracellular calcium levels induced by Gq mediat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
US Patent

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 4.62E+3nMpH: 7.4 T: 2°CAssay Description:Prokineticin receptor 1 (PKR1) antagonists may be functionally assessed by measurement of change in intracellular calcium levels induced by Gq mediat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2017
Entry Details
US Patent

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 4.62E+3nMAssay Description:Prokineticin receptor 1 (PKR1) antagonists may be functionally assessed by measurement of change in intracellular calcium levels induced by Gq mediat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 4.62E+3nMAssay Description:The ability of a compound to block the intracellular release of calcium mediated by PK1 in RBL2H3 cells expressing human PKR1 receptors is determined...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2023
Entry Details
US Patent

TargetProkineticin receptor 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM250617(US9475795, 98 | US9475795, 97 | US9475795, 96 | US...)
Affinity DataIC50: 4.62E+3nMAssay Description:Prokineticin receptor 1 (PKR1) antagonists may be functionally assessed by measurement of change in intracellular calcium levels induced by Gq mediat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
US Patent